Literature DB >> 28993478

Effect of Mutant p53 Proteins on Glycolysis and Mitochondrial Metabolism.

Matilda Eriksson1, Gorbatchev Ambroise1, Amanda Tomie Ouchida1, Andre Lima Queiroz1, Dominique Smith1, Alfredo Gimenez-Cassina2,3, Marcin P Iwanicki4, Patricia A Muller5, Erik Norberg6, Helin Vakifahmetoglu-Norberg6.   

Abstract

TP53 is one of the most commonly mutated genes in human cancers. Unlike other tumor suppressors that are frequently deleted or acquire loss-of-function mutations, the majority of TP53 mutations in tumors are missense substitutions, which lead to the expression of full-length mutant proteins that accumulate in cancer cells and may confer unique gain-of-function (GOF) activities to promote tumorigenic events. Recently, mutant p53 proteins have been shown to mediate metabolic changes as a novel GOF to promote tumor development. There is a strong rationale that the GOF activities, including alterations in cellular metabolism, might vary between the different p53 mutants. Accordingly, the effect of different mutant p53 proteins on cancer cell metabolism is largely unknown. In this study, we have metabolically profiled several individual frequently occurring p53 mutants in cancers, focusing on glycolytic and mitochondrial oxidative phosphorylation pathways. Our investigation highlights the diversity of different p53 mutants in terms of their effect on metabolism, which might provide a foundation for the development of more effective targeted pharmacological approaches toward variants of mutant p53.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  EMT; OxPhos; cancer; glycolysis; metabolism; mutant p53

Mesh:

Substances:

Year:  2017        PMID: 28993478      PMCID: PMC5705820          DOI: 10.1128/MCB.00328-17

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  39 in total

1.  Gain-of-function mutant p53 promotes cell growth and cancer cell metabolism via inhibition of AMPK activation.

Authors:  Ge Zhou; Jiping Wang; Mei Zhao; Tong-Xin Xie; Noriaki Tanaka; Daisuke Sano; Ameeta A Patel; Alexandra M Ward; Vlad C Sandulache; Samar A Jasser; Heath D Skinner; Alison Lea Fitzgerald; Abdullah A Osman; Yongkun Wei; Xuefeng Xia; Zhou Songyang; Gordon B Mills; Mien-Chie Hung; Carlos Caulin; Jiyong Liang; Jeffrey N Myers
Journal:  Mol Cell       Date:  2014-05-22       Impact factor: 17.970

Review 2.  Mutant p53 gain-of-function in cancer.

Authors:  Moshe Oren; Varda Rotter
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-02       Impact factor: 10.005

Review 3.  Otto Warburg's contributions to current concepts of cancer metabolism.

Authors:  Willem H Koppenol; Patricia L Bounds; Chi V Dang
Journal:  Nat Rev Cancer       Date:  2011-04-14       Impact factor: 60.716

4.  Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis.

Authors:  W Hanel; N Marchenko; S Xu; S Xiaofeng Yu; W Weng; U Moll
Journal:  Cell Death Differ       Date:  2013-03-29       Impact factor: 15.828

5.  A common gain of function of p53 cancer mutants in inducing genetic instability.

Authors:  D P Liu; H Song; Y Xu
Journal:  Oncogene       Date:  2009-11-02       Impact factor: 9.867

6.  Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma.

Authors:  Pilar Caro; Amar U Kishan; Erik Norberg; Illana A Stanley; Bjoern Chapuy; Scott B Ficarro; Klaudia Polak; Daniel Tondera; John Gounarides; Hong Yin; Feng Zhou; Michael R Green; Linfeng Chen; Stefano Monti; Jarrod A Marto; Margaret A Shipp; Nika N Danial
Journal:  Cancer Cell       Date:  2012-10-16       Impact factor: 31.743

7.  Tumor spectrum analysis in p53-mutant mice.

Authors:  T Jacks; L Remington; B O Williams; E M Schmitt; S Halachmi; R T Bronson; R A Weinberg
Journal:  Curr Biol       Date:  1994-01-01       Impact factor: 10.834

8.  Mutant p53 drives invasion by promoting integrin recycling.

Authors:  Patricia A J Muller; Patrick T Caswell; Brendan Doyle; Marcin P Iwanicki; Ee H Tan; Saadia Karim; Natalia Lukashchuk; David A Gillespie; Robert L Ludwig; Pauline Gosselin; Anne Cromer; Joan S Brugge; Owen J Sansom; Jim C Norman; Karen H Vousden
Journal:  Cell       Date:  2009-12-24       Impact factor: 41.582

9.  p53 gene mutations and protein accumulation in human ovarian cancer.

Authors:  J Kupryjańczyk; A D Thor; R Beauchamp; V Merritt; S M Edgerton; D A Bell; D W Yandell
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

10.  Degradation of HK2 by chaperone-mediated autophagy promotes metabolic catastrophe and cell death.

Authors:  Hong-Guang Xia; Ayaz Najafov; Jiefei Geng; Lorena Galan-Acosta; Xuemei Han; Yuan Guo; Bing Shan; Yaoyang Zhang; Erik Norberg; Tao Zhang; Lifeng Pan; Junli Liu; Jonathan L Coloff; Dimitry Ofengeim; Hong Zhu; Kejia Wu; Yu Cai; John R Yates; Zhengjiang Zhu; Junying Yuan; Helin Vakifahmetoglu-Norberg
Journal:  J Cell Biol       Date:  2015-08-31       Impact factor: 10.539

View more
  31 in total

1.  PD-L1 on invasive fibroblasts drives fibrosis in a humanized model of idiopathic pulmonary fibrosis.

Authors:  Yan Geng; Xue Liu; Jiurong Liang; David M Habiel; Vrishika Kulur; Ana Lucia Coelho; Nan Deng; Ting Xie; Yizhou Wang; Ningshan Liu; Guanling Huang; Adrianne Kurkciyan; Zhenqiu Liu; Jie Tang; Cory M Hogaboam; Dianhua Jiang; Paul W Noble
Journal:  JCI Insight       Date:  2019-03-21

2.  Ethyl isopropyl amiloride decreases oxidative phosphorylation and increases mitochondrial fusion in clonal untransformed and cancer cells.

Authors:  Sagar S Manoli; Kyle Kisor; Bradley A Webb; Diane L Barber
Journal:  Am J Physiol Cell Physiol       Date:  2021-05-26       Impact factor: 5.282

3.  The complexity of p53-mediated metabolic regulation in tumor suppression.

Authors:  Yanqing Liu; Wei Gu
Journal:  Semin Cancer Biol       Date:  2021-03-27       Impact factor: 17.012

4.  Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic properties.

Authors:  James A McCubrey; Akshaya K Meher; Shaw M Akula; Stephen L Abrams; Linda S Steelman; Michelle M LaHair; Richard A Franklin; Alberto M Martelli; Stefano Ratti; Lucio Cocco; Fulvio Barbaro; Przemysław Duda; Agnieszka Gizak
Journal:  Aging (Albany NY)       Date:  2022-04-27       Impact factor: 5.682

5.  MicroRNA200a enhances antitumor effects in combination with doxorubicin in hepatocellular carcinoma.

Authors:  Xiao Cui; Dachen Zhou; Qiang Du; Peiqi Wan; Kun Dong; Hui Hou; David A Geller
Journal:  Transl Oncol       Date:  2020-06-17       Impact factor: 4.243

6.  O-GlcNAcylation on Rab3A attenuates its effects on mitochondrial oxidative phosphorylation and metastasis in hepatocellular carcinoma.

Authors:  Weicheng Wu; Xixi Zheng; Jing Wang; Tianxiao Yang; Wenjuan Dai; Shushu Song; Lan Fang; Yilin Wang; Jianxin Gu
Journal:  Cell Death Dis       Date:  2018-09-20       Impact factor: 8.469

7.  Mutant p53 blocks SESN1/AMPK/PGC-1α/UCP2 axis increasing mitochondrial O2-· production in cancer cells.

Authors:  Marco Cordani; Giovanna Butera; Ilaria Dando; Margalida Torrens-Mas; Elena Butturini; Raffaella Pacchiana; Elisa Oppici; Chiara Cavallini; Sara Gasperini; Nicola Tamassia; Mercedes Nadal-Serrano; Michela Coan; Davide Rossi; Gianluca Gaidano; Michele Caraglia; Sofia Mariotto; Riccardo Spizzo; Pilar Roca; Jordi Oliver; Maria Teresa Scupoli; Massimo Donadelli
Journal:  Br J Cancer       Date:  2018-10-15       Impact factor: 7.640

Review 8.  Metabolic Reprogramming of Colorectal Cancer Cells and the Microenvironment: Implication for Therapy.

Authors:  Miljana Nenkov; Yunxia Ma; Nikolaus Gaßler; Yuan Chen
Journal:  Int J Mol Sci       Date:  2021-06-10       Impact factor: 5.923

9.  Mitochondrial estrogen receptors alter mitochondrial priming and response to endocrine therapy in breast cancer cells.

Authors:  Bahriye Karakas; Yeliz Aka; Asli Giray; Sehime Gulsun Temel; Ufuk Acikbas; Huveyda Basaga; Ozgur Gul; Ozgur Kutuk
Journal:  Cell Death Discov       Date:  2021-07-22

Review 10.  The p53 Tumor Suppressor in the Control of Metabolism and Ferroptosis.

Authors:  Keerthana Gnanapradeepan; Subhasree Basu; Thibaut Barnoud; Anna Budina-Kolomets; Che-Pei Kung; Maureen E Murphy
Journal:  Front Endocrinol (Lausanne)       Date:  2018-04-11       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.